FDA Approves Perrigo’s Generic Ofirmev

The FDA has provided Perrigo with final approval to produce its generic version of Mallinckrodt Pharmaceuticals’ Ofirmev injection 1000 mg/100 mL. Perrigo will not be able to launch the drug until December 6th, 2020, and under an agreement with Mallinckrodt, will be the sole generic distributor of the drug if Mallinckrodt decides to launch an authorized generic product.

Read the source article at PR Newswire